Focused Clinical Research Coordinator well-versed in study protocols, standard operating procedures and general trial oversight. Excellent problem-solving abilities with a detail-oriented nature. Ready to bring [Number] years of related experience to a challenging new role.
Joanna Figueroa “Elevated Liver Enzymes in Asymptomatics”
Department of Internal Medicine
Weis Memorial Hospital
Joanna Figueroa “Hepatitis B Serology”
Department of Internal Medicine Morning Rounds
Larkin Community Hospital
Joanna Figueroa “CNS Demyelinating and Inflammatory Disease”
Department of Neurology
Chong Hua Hospital
Joanna Figueroa “HIV Prophylaxis Management”
Department of Family Medicine Morning Rounds
Chong Hua Hospital
Joanna Figueroa “A Case of Terminal Dysuria”
Department of Internal Medicine Grand Rounds
Chong Hua Hospital
Joanna Figueroa “Persistent Left Superior Vena Cava”
Department of Pediatrics Grand Rounds
John H. Stroger Hospital
Joanna Figueroa “Preventative Health Care for Women”
Educational Class for Women
Gullas Health Community Center
“Stress Levels of First Year to Third Year Regular Students of Gullas College of Medicine”
Department of Pharmacology and Therapeutics
Gullas College of Medicine
“The Effectivity of Moringa oliefera extract on inhibition of Methicillin Resistant Staphylococcus Aureus in Comparison to Vancomycin”
Departement of Pharmacology
Cebu Institute of Medicine
1. Biohaven Pharmaceuticals, Inc.
“BHV3500-202: A phase 2/3 Open-label, Long-Term, Safety Trial of BHV-3500 (zavegepant) intranasal (IN) for the Acute Treatment of Migraine”
2. AbbVie, Inc.
“A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis”
3. AbbVie, Inc.
“Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study”
4. Abbvie Inc.
“A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to Severe Plaque Psoriasis”
5. Biohaven Pharmaceuticals, Inc.
“A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
6. Eli Lilly and Company
“The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)”
7. Esperion Therapeutics, Inc
“A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant”
8. Kowa Research Institute, Inc.
“Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT)”
9. Novo Nordisk
“SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity”
9. Novo Nordisk
10. Novo Nordisk
“Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)”
11. Tonix Pharmaceuticals, Inc.
“A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily At Bedtime In Patients with Fibromyalgia, "RELIEF Study”
12. Dyve Biosciences
“Randomized, double-blinded, placebo-controlled study of the efficacy and safety of DYV700 for reducing pain associated with an acute gout flare”
13. Samumed, LLC
“A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects”
14. Samumed, LLC
“A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
15. GlaxoSmithKline Research & Development Limited
“A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors”
16. GlaxoSmithKline Research & Development Limited
“A multi-centre long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis.”
17. AOBiome Therapeutics
“A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults with a History of Atopic Dermatitis”
18. DS Biopharma
“A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis”
19. Quantum Genomics
“A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subject”
20. Concert Pharmaceuticals
“A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata”
“A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy”
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Companies Worked For:
Job Titles Held: